Vitamin D3 potentiates the antitumorigenic effects of arsenic trioxide in human leukemia (HL-60) cells by Christian S Rogers et al.
Experimental 
Hematology & Oncology
Rogers et al. Experimental Hematology & Oncology 2014, 3:9
http://www.ehoonline.org/content/3/1/9RESEARCH Open AccessVitamin D3 potentiates the antitumorigenic effects
of arsenic trioxide in human leukemia (HL-60) cells
Christian S Rogers, Clement G Yedjou, Dwayne J Sutton and Paul B Tchounwou*Abstract
Background: Arsenic trioxide (ATO) is a novel form of therapy that has been found to aid acute promyelocytic
leukemia (APL) patients. Our laboratory has demonstrated that ATO-induced cytotoxicity in human leukemia (HL-60)
cells is mediated by oxidative stress. Pro-oxidants have been known to play a role in free radical-mediated oxidative
stress. Vitamin D3, (Vit D3) an active metabolite of vitamin D has been reported to inhibit the growth of number
neoplasms such as prostate, breast, colorectal, leukemia, and skin cancers. The goal of the present research was to
use (HL-60) cells as an in vitro test model to evaluate whether low doses of Vit D3 potentiate the toxicity of ATO
and whether this toxic action is mediated via apoptotic mechanisms.
Method: HL-60 cells were treated either with a pharmacologic dose of ATO alone and with several low doses of Vit
D3. Cell survival was determined by MTT assay. Cell apoptosis was measured both by flow cytometry assessment,
and DNA laddering assay.
Results: MTT assay indicated that Vit D3 co-treatment potentiates ATO toxicity in HL-60 cells in a dose dependent
manner. A statistically significant and dose-dependent increase (p <0.05) was recorded in annexin V positive cells
(apoptotic cells) with increasing doses of Vit D3 in ATO-treated cells. This finding was confirmed by the result of
DNA laddering assay showing clear evidence of nucleosomal DNA fragmentation in vitamin and ATO co-treated
cells.
Conclusion: The present study indicates that Vit D3 potentiates the antitumor effects of ATO. This potentiation is
mediated at least in part, through induction of phosphatidylserine externalization and nucleosomal DNA
fragmentation. These findings highlight the potential impact of Vit D3 in promoting the pharmacological effect of
ATO, suggesting a possible future role of Vit D3/ATO combination therapy in patients with acute promyelocytic
leukemia (APL).
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Acute promyelocytic leukemia (APL) is a subtype of the
acute myeloid leukemia (AML). APL is characterized by
abnormal, heavily granulated promyelocytes, a form of
white blood cells. APL results in the accumulation of
these atypical promyelocytes in the bone marrow and
peripheral blood, and replaces normal blood cells. The
standard treatment of this disease is chemotherapy and
all trans-retinoic acid. Interestingly, arsenic trioxide
(ATO) is a new form of therapy that has been found to
benefit APL patients. Both in vitro and in vivo studies* Correspondence: paul.b.tchjounwou@jsums.edu
Environmental Toxicology Research Laboratory, NIH-Center for Environmental
Health College of Science, Engineering and Technology, Jackson State
University, 1400 Lynch Street, Box 18540, Jackson, MS 39217, USA
© 2014 Rogers et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.have shown that ATO can induce clinical remission of
de novo and relapsed APL patients [1,2]. Several studies
have reported that ATO induces apoptosis in malignant
cells including APL, non-Hodgkin’s lymphoma, multiple
myeloma, and chronic lymphocytic leukemia cells [3-5].
Also, ATO has been found to induce apoptosis in myeloid
leukemia cells such as U937 and KG-1 cells [6]. ATO in-
duced apoptosis is associated with the generation of react-
ive oxygen species that contribute significantly to cell
killing [7-9] and inhibition of growth [10].
Vitamin D was discovered by Edward Mellanby in
1919 during his classic experiments with rickets [11]. It
is classified into five forms including vitamin D2 (ergos-
terol); vitamin D3 (cholecalciferol); vitamin D4 (22, 23Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lecal- ciferol]); and vitamin D6 (stigmasterol) [12]. Vitamin
D influences almost every cell in the body, and it is one of
nature’s most potent cancer fighting agents. The receptors
that respond to Vitamin D convert it to calcitrol which
is a hormone. The Body organs use calcitol to repair
damage and eradicate cancer cells. Experimental studies
have shown that vitamin D is able to enter cancer cells
and trigger apoptosis or cancer cell death. It is as effective
at killing cancer cells in a way similar to the cancer drug
Tamoxifen, and without the side effects.
A preclinical study indicated that exposing cancer cells
and vascular endothelial cells to high concentrations of
active metabolites of Vit D3 halts progression through
growth arrest, apoptosis and cell cycle arrest in vivo [13].
Vit D3 potentiates the antitumor activity of a number of
types of cytotoxic anticancer agents in in vivo preclinical
models. Vit D3 analogues initiate signaling through a
number of important pathways, but the pathway essen-
tial to the antitumor activities of Vit D3 are unclear [14].
Since both ATO and Vit D3 have been found to induce
apoptosis in a variety of cancer cells, we designed this
present study to evaluate the combined effect of both
compounds. Also the mechanisms of action of VitD3 in
combination with ATO for the treatment of APL remain
largely unknown. Therefore, the aim of this research was
to use human leukemia (HL-60) APL-cells as an in vitro
test model to determine the potential mechanism of ac-
tion of VitD3 on ATO chemotherapy of APL.
Results
Vitamin D3 potentiates the cytotoxicity of arsenic trioxide
in HL-60 cells
We have previously reported that physiologic doses of
ATO increase cellular proliferation while pharmacologicFigure 1 Toxicity of arsenic trioxide to human leukemia (HL-60) cells.
24 hr as indicated in the Materials and Methods. Cell viability was determin
experiments with 6 replicates per dose. *Significantly different (p < 0.05) frodoses of ATO were highly cytotoxic to HL-60 cells,
showing a 24 hr LD50 of 6.4 ± 0.6 μg/mL [15]. As shown
in (Figure 1), a single pharmacologic dose (6 μg/mL) of
ATO is highly cytotoxic to HL-60 cells. Low doses of Vit
D3 have no effects on cell growth while on the other
hand high doses inhibit the growth of HL-60 cells and
cause significant cell death. Low doses of Vit D3 were se-
lected based on the data generated from the MTT assay
(Figure 2). Co-treatment of these cells using low doses
(0.5-1.5 μM) of Vit D3 and a pharmacologic dose (6 μg/mL)
of ATO resulted in a higher level of cell death than
did ATO alone. We found that the viability of HL-60
cells declined from (62 ± 5)% in cells treated with ATO
alone to (44 ± 3)% in cells co-treated with 1.5 μM Vit D3
and 6 μg/mL ATO with P < 0.05 (Figure 3).
Vitamin D3 potentiates arsenic trioxide-induced apoptosis
in HL-60 cells
To determine whether low doses of VitD3 could sensitize
arsenic trioxide (ATO)-mediated apoptosis, HL-60 cells
were treated for 24 hr, subsequently stained with
annexin V/PI, and analyzed by flow cytometry. As
shown in (Figures 4 and 5), Vit D3 enhances the pro-
portion of cells undergoing apoptosis in ATO-treated
cells compared to ATO alone. For example, the propor-
tion of annexin V positive was (38 ± 5)% in cells treated
with 6 μg/mL ATO alone and (57 ± 6)% in cells treated
with 1.5 μM Vit D3 plus 6 μg/mL ATO with P < 0.05.
Vitamin D3 potentiates arsenic trioxide-induced
nucleosomal DNA fragmentation in HL-60 cells
In this study, we used camptothecin (CAM) as a positive
control for DNA fragmentation because it is potent in-
hibitor of topoisomerase I and induces DNA fragmentation
in a dose-dependent manner. Our results demonstratedHL-60 cells were cultured with different doses of arsenic trioxide for
ed based on the MTT assay. Each point represents a mean ± SD of 3
m the control, according to the Dunnett’s test [15].
Figure 2 Effect of vitamin D3 (Vit D3) on human leukemia (HL-60) cells. HL-60 cells were cultured with different doses of Vit D3 for 24 hr as
indicated in the Materials and Methods. Cell viability was determined based on the MTT assay. Each point represents a mean value and standard
deviation of 3 experiments with 6 replicates per dose. *Significantly different (p < 0.05) from the control, according to the Dunnett’s test.
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Vit D3 concentrations of (0.5, 1.0, 1.5 μM) and 6 μg/mL
ATO combined, upon 24-hr incubation with HL-60 cells.
As seen in the dose–response experiments of the present
study, the extent of DNA fragmentation increased propor-
tionately with increasing doses of Vit D3, suggesting that
Vit D3 potentiates ATO induced apoptosis in HL-60 cells
in a dose-dependent manner (Figure 6).
Discussion
Several experimental studies have suggested a possible as-
sociation between vitamin D and cancer risk reduction.
For instance, in vitro and in vivo studies with cancer cells
and tumors in mice found that vitamin D has severalFigure 3 Cytotoxic effect of VitD3 and ATO combination treatment on
absence or presence of vitD3 and ATO or in combination of VitD3 and ATO
determined based on the MTT assay. Each point represents a mean value a
*Significantly different from the control by ANOVA Dunnett’s test; p < 0.05.
test; p < 0.05.activities that might slow and/or prevent the development
of cancer, including promoting cellular differentiation, de-
creasing cancer cell growth, stimulating cell death, and re-
ducing tumor blood vessel formation [16-18].
Arsenic trioxide (ATO) has previously been reported
to be cytotoxic to various mammalian cancer cell lines
[10,19]. Data obtained from the present study indicate
that the combination of low doses of vitamin D3 plus a
pharmacologic dose of ATO is more cytotoxic to human
promyelocytic leukemia (HL-60) cells compared to ATO
alone. We found that Vit D3 co-treatment enhances
ATO toxicity in HL-60 cells in a dose dependent man-
ner. Consistent with the present study, previous by pub-
lished reports from our laboratory demonstrated thathuman leukemia (HL-60) cells. HL-60 cells were cultured in the
for 24 hr as indicated in the Materials and Methods. Cell viability was
nd standard deviation of 3 experiments with 6 replicates per dose.
**Significantly different from ATO alone by ANOVA Dunnett’s
Figure 4 Representative flow cytometry analysis data from Annexin V-FITC staining. The histogram shows a comparison of the distribution
of negative annexin V cells (M1) and positive annexin V cells (M2) after 24 hr incubation in HL-60 cells. A = control; B =6 μg/mL ATO; C = 0.5 μM
VitD3 + 6 μg/mL ATO; D = 1.0 μM VitD3 + 6 μg/mL ATO; E = 1.5 μM VitD3 6 μg/mL ATO.
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cells [20]. High doses of Vit D3 treatment alone prove to
be cytotoxic, suggesting that it has the potential to be
an enabling agent that sensitizes tumor cells to the cyto-
toxic effect of ATO-based chemotherapy. Vit D3 has beenFigure 5 Annexin V-FITC positive cells induced by either arsenic triox
HL-60 cells. Each point represents the mean value and the standard devia
different from control (0 μg/mL), p < 0.05.found to play an important role in controlling calcium
homeostasis and bone metabolism [21,22] and in prevent-
ing diabetes [23]. Vit D3 induces monocytic differentiation
in human myeloid leukemia cells including HL-60 myelo-
blastic cells [24].ide alone or vitamin D3 and arsenic trioxide combination in
tion of three experiments, showing similar results. *Significantly
Figure 6 Induction of DNA fragmentation in HL-60 cells. Lane 1:
M-Molecular weight marker. Lane 2-Positive control marker/
Camptothecin (5 μM). Lane 3- ATO alone (6 μg/mL). Lane 4- Control
with no treatment. Lane 5- VitD3 (0.5 μM) + ATO (6 μg/mL ATO); Lane
6- VitD3 (1.0 μM) + ATO (6 μg/mL ATO); Lane 7- VitD3 (1.5 μM) + ATO
(6 μg/mL ATO). HL-60 celles were treated for 24 hr. The DNA gel was
stained with SYBR Green 1 after electrophoresis on a 1% agarose gel
and then analyzed on the Typhoon 9400 phospho imager.
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ATO toxicity in cancer cells may be mediated via apop-
tosis, we assessed annexin V FITC/PI staining using the
flow cytometry analysis. The flow cytometry data show a
significant increase in annexin V positive cells (apoptotic
cells) in Vit D3 co-treated cells with ATO compared to
ATO alone (Figures 3 and 4). The percentage of annexin
V cells positive was 38 ± 5% in cells treated with 6 μg/mL
ATO and 57 ± 6% in those treated with 1.5 μM AA plus
6 μg/mL ATO with p < 0.05. By the means of flow cytom-
etry, we report for the second time in our laboratory that
antioxidant agents including ascorbic acid and Vit D3 po-
tentiate the activity of ATO in cancer cells via phosphati-
dylserine externalization as result of the loss of membrane
integrity, a major characteristic of cell death by apoptosis
[10].
To confirm the apoptotic mechanism of Vit D3 on
ATO, we further examined the apoptotic response, as
judged by the appearance of a DNA ladder. A character-
istic pattern of nucleosomal DNA fragmentation, which
is the hallmark of apoptosis, was detected in ATO-
treated cells alone and in Vit D3 plus ATO-treated cells
(Figure 5). As seen in the dose–response experiment of
the present study, the extent of DNA fragmentation in-
creased proportionately with increasing doses of Vit D3,
suggestive that Vit D3 potentiates ATO-inducedapoptosis in HL-60 cells in a dose-dependent manner.
Apoptosis usually is defined as programmed cell death
and is characterized by specific morphologic features in-
cluding cytoplasmic shrinkage, chromatin condensation,
membrane blebbing, endonucleolytic degradation of gen-
omic DNA, and the formation of apoptotic bodies [25,26].
There is evidence that apoptosis plays a role in the re-
sponse of leukemia patients to chemotherapy, and there is
probably an association between therapy-induced apop-
tosis and therapeutic efficacy [27,28].
Both the flow cytometry assessment and DNA ladder-
ing assay clearly demonstrated that co-administration of
Vit D3 potentiated the apoptotic effects in ATO-treated
HL-60 cells. Thus, confirming the enabling ability of Vit
D3 on ATO. Although the mechanism by which Vit D3
enhances ATO-mediated cytotoxicity in HL-60 cells re-
mains unknown, here we provided clear evidence that
Vit D3 potentiates the antitumor effects of ATO, and
this potentiation is mediated at least in part, via activa-
tion of phosphatidylserine externalization and nucleo-
somal DNA fragmentation.
Conclusion
Given all the above, it is reasonable to infer that low
doses of Vit D3 do not significantly affect cell viability
in vitro while high doses of this compound are moder-
ately toxic to HL-60 cells. We explore the cytotoxic and
apoptotic effects of low doses of Vit D3 on the activity of
ATO in human leukemia cells. The results of the MTT
assay indicated that low doses of Vit D3 treatment sig-
nificantly increase ATO toxicity in HL-60 cells in a dose
dependent manner compared to ATO alone. This is
most probably due to the different mechanisms through
which both Vit D3 and ATO kill HL-60 cells. While test-
ing the apoptotic mechanisms of these two compounds,
both the flow cytometry assessment and DNA laddering
evaluation showed an increase apoptotic cell death in
cells co-treated with Vit D3 plus ATO compared to ATO
alone, suggesting that Vit D3 acts as pro-oxidant in the
presence of ATO. Given the recent therapeutic progress
in the treatment of APL with ATO (Trisenox), we be-
lieve that the combination of Vit D3 plus ATO is a
promising candidate for a novel therapeutic approach in
the management of APL However further clinical trials
are needed to confirm this finding.
Methods
Chemicals and test media
Arsenic trioxide, Lot No. 091419, CASRN 1327-53-3,
MW 197.84, with an active ingredient of 100% (w/v) ar-
senic in 10% nitric acid was purchased from Fisher
Scientific (Houston Texas). Vitamin D3, Lot No. 120M1635V
was purchased from Sigma Aldrich (St. Louis, MO).
Growth medium RPMI 1640 containing 1 mmol/L L-
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from Gibco BRL products (Grand Island, NY). Penicillin-
Streptomycin, Lot No. 3000880, phosphate buffered saline
(PBS-pH 7.4) Lot No. 3000892, and MTT assay kit Lot
No. 3000800 were obtained from the American Type Cul-
ture Collection - ATCC (Manassas, VA). Annexin V-FITC
Apoptosis Detection Kit Lot No. 42191 was purchased
from BD Biosciences (San Diego, CA). Apoptotic DNA-
Ladder kit, Lot No. 11324200 was purchased from Roche
Molecular Biochemicals (Indianapolis, IN).
Cell culture
The HL-60 promyelocytic leukemia cell line (No. CCL-240)
was purchased from the American Type Culture Collection-
ATCC (Manassas, VA). This cell line has been derived
from peripheral blood cells of a 36-year old Caucasian fe-
male with acute promyelocytic leukemia (APL). The HL-
60 cells grow as a suspension culture. In the laboratory,
cells were stored in the liquid nitrogen until use. They
were next thawed by gentle agitation of their containers
(vials) for 2 minutes in a water bath at 37°C. After thaw-
ing, the content of each vial of cell was transferred to a
100 mm tissue culture dish, diluted with up to 20 ml of
RPMI 1640 containing 1 mmol/L glutamine and supple-
mented with 10% (v/v) fetal bovine serum (FBS), and 1%
(w/v) penicillin/streptomycin. The 100 mm culture dish,
containing 2 × 106 viable cells, were observed under the
microscope, followed by incubation in a humidified 5%
CO2 incubator at 37°C. Three times a week, they were
diluted under same conditions to maintain a density of
5 × 105/mL, and harvested in the exponential phase of
growth.
Treatment and measurement of cell viability
To explore the effect of vitamin (Vit D3) on the via-
bility of HL-60 cells, 1 ml aliquots of cell suspension
were transferred into 24 well tissue culture plates and
treated with 1000 μM of Vit D3 diluted to reach final
doses of .78, 1.56, 3.12, 6.25,12.5, and 25 μM cholecalcif-
erol. Cells were placed in the humidified 5% CO2 incu-
bator at 37°C for 24 hr. Cells incubated in culture
medium alone served as a control (untreated wells). After
incubation, 200 μL aliquots of MTT solution were added
to each well and re-incubated for 30 min at 37°C, followed
by low centrifugation at 800 rpm for 5 min. The super-
natants were carefully aspirated and 200 μL aliquots
of dimethylsulfoxide (DMSO) were added to each well
to dissolve the formazan crystals, followed by incuba-
tion for 10 min to dissolve air bubbles. The culture
plates were placed on a Multiskan micro-plate reader
and the absorbance was measured at 570 nm. The
amount of color produced is directly proportional to
the number of viable cells. All assays were performed
in three replicates for each, Vit D3, ATO, or Vit D3 +ATO concentration, and means ± SD values were cal-
culated. Cell viability rate was calculated as the per-
centage of MTT absorption as follows: % survival =
(mean experimental absorbance/mean control absorb-
ance) × 100. In a recently published experiment, we
reported that ATO is cytotoxic to HL-60 cells, show-
ing a 24 hr LD50 of 6.4 ± 0.6 μg/mL [14]. Hence, to
examine the effect of Vit D3 on ATO-induced cyto-
toxicity, cells were exposed to 0.5, 1.0 and 1.50 μM
of VitD3 for 30 min and then co-exposed to 6 μg/mL
ATO and incubated in humidified 5% CO2 incubator
at 37°C for 24 hr, and tested for cell viability follow-
ing the MTT assay protocol as described above.
Flow cytometric analysis of phosphatidylserine
externalization
The ability of cells to actively undergo apoptosis depends
on their characteristic to lose membrane asymmetry in
early phases of the apoptosis process. This early marker
of programmed cell death is determined by analyzing
phosphatidylserine (PS) translocation from the inner
compartment of the plasma membrane to the outer
compartment, thereby exposing PS to the external envir-
onment. Since Annexin V has a high affinity for PS it is
effectively used in identifying apoptotic cells. Propidium
iodide (PI) is a standard cytometric viability probe and is
used to differentiate viable from nonviable cells. Viable
cells with intact membranes exclude PI, whereas the
membranes of dead and damaged cells are permeable
to PI. HL-60 cells were double stained with a FITC-
conjugated Annexin V antibody and PI (1 μg/mL) BD
Biosciences (San Diego, CA) and analyzed by flow cy-
tometry (FACSCalibur and Cell Quest Pro Software, BD
Biosciences, San Diego, CA). HL-60 cells were treated
with low doses of Vit D3 for 30 min prior and then treated
with 6 μg/mL ATO for 24 hours. After treatment, 1 × 106
cells/mL were washed with cold PBS and then resus-
pended in 1X binding buffer. One hundred (100) μL
of the solution was transferred to a culture tube where
5 μL of both Annexin V-FITC and PI were added. The
solution was mixed and then incubated for 15 min at
room temperature in the dark. An additional 400 μL
of 1X binding buffer was added to each tube and flow
cytometric analysis was performed within 30 min of
staining. A histogram analysis acquiring 10,000 events
using M1 and M2 gates demonstrated viable cells ver-
sus nonviable cells. Results were analyzed and statis-
tical analysis done using the Cell Quest Pro software
BD Biosciences.
Apoptosis DNA laddering assay
The purification of total DNA from HL-60 cells exposed
to ATO alone and ATO +Vit D3 was done and DNA
fragmentation analysis was performed to confirm the
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hallmark of apoptotic cells. The apoptotic DNA Ladder
kit from Roche Molecular Biochemicals (Indianapolis, IN)
was used as directed. A sample volume of 800 μL contain-
ing 2 × 106 cells was combined with binding buffer and
incubated for 10 min at room temperature. Isopropanol
was added to the sample and vortex. The sample mixture
was added to the upper reservoir of the filter tube and
centrifuged for 1 min at 8,000 rpm. The flow through
was discarded and 500 μL of washing buffer was added to
the upper reservoir and centrifuged for 1 minute at
8,000 rpm. The flow through was discarded and a final
centrifugation was performed for 10 sec at 13,000 rpm to
remove residual wash buffer. The filter tube was inserted
into a clean 1.5 mL tube. The DNA was extracted by add-
ing 800 μl of elution buffer and centrifuge for 1 min at
8,000 rpm. A higher dilution volume was used to increase
the elution efficiency. Total DNA was measured by re-
moving 1 μL from each sample and adding it to 999 μL of
distilled H2O and reading the absorbance on a spectro-
photometer. The optical density (OD) reading was multi-
plied by 50 μg/ml and the amount of DNA needed to add
to the agarose gel was calculated to be 3 μL for each sam-
ple. The agarose gels were run in TBE (Tris-borate EDTA)
buffer at 75 volts until the marker migrated to approxi-
mately 2 cm above the end of the chamber. The gel was
stained with SYBR Green 1 for 24 hours and analyzed on
the Typhoon 9400 phospho imager from GE Healthcare
(Piscataway, NJ).
Statistical analysis
Experiments were performed in triplicates. Data were
presented as means ± SDs. Where appropriate, one-way
ANOVA or student paired t-test was performed using
SAS Software available in the Biostatistics Core Labora-
tory at Jackson State University. P-values less than 0.05
were considered statistically significant.
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